| Drug Name |
Mannitol |
| Drug ID |
BADD_D01349 |
| Description |
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid.
On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chiesi USA Inc.[L20024] |
| Indications and Usage |
Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
A06AD16; B05BC01; B05CX04; R05CB16; V04CX04 |
| DrugBank ID |
DB00742
|
| KEGG ID |
D00062
|
| MeSH ID |
D008353
|
| PubChem ID |
6251
|
| TTD Drug ID |
D0P7EK
|
| NDC Product Code |
0264-7578; 58103-137; 63323-024; 51552-0380; 10122-212; 14639-5303; 0338-0355; 58103-135; 52584-031; 0990-7715; 0404-9905; 0338-0353; 0409-4031; 0338-0357; 38779-0599; 67850-552; 51662-1468; 50516-002 |
| Synonyms |
Mannitol | Osmitrol | Osmofundin | (L)-Mannitol |
